Therapy Areas: Diabetes
BrightGene presents BGM0504 positive Phase 2 data for weight management and type 2 diabetes
24 June 2025 - Chinese pharmaceutical company BrightGene Pharmaceutical Co Ltd announced on Tuesday that it has presented data from two Phase 2 studies for BGM0504, its investigational dual agonist ta...
Amgen reports results of Phase 2 MariTide obesity study
24 June 2025 - US pharmaceutical company Amgen (NASDAQ:AMGN) on Monday reported full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, pe...
European Medicines Agency recommends approval of Alvotech's biosimilar to Eylea
23 June 2025 - Biotechnology company Alvotech SA (NASDAQ:ALVO) announced on Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinio...
Gan & Lee presents trial results for novel diabetes therapies at ADA's 85th Scientific Sessions
23 June 2025 - Chinese pharmaceutical company Gan & Lee Pharmaceuticals (SH:603087) announced on Saturday that it presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 recep...
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
18 June 2025 - TME Pharma N.V. (Euronext Growth Paris: ALTME) announced on Wednesday that it has signed an option framework agreement with the Singapore Eye Research Institute (SERI) to advance the de...
Innovent reports first participant dosed in new Phase 3 trial of mazdutide in China
16 June 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-OSA) ...